This is the 21st century news daily, where we welcome the latest events in the pharmaceutical and health industry with the new 21st century economics team
Policy developments
New office of the united nations high commissioner for human rights (unhcr) briefing on the development of a sound mechanism for full-cycle drug price formation
In the morning of 15 april, the press office of the state council held a routine policy briefing in which the heads of the national health insurance agency, the ministry of industry and information technology, the national health and health commission, the general directorate of market supervision and the national drug control and drug administration, provided information on the mechanism for the formation of a full-cycle, sound drug price。
The deputy director-general of the national health insurance agency, shi zhihai, described the opinion as upholding a people-centred approach to development, making full use of the decisive role of the market in the allocation of resources, making better use of the role of the government, strengthening market-led drug price formation mechanisms, supporting quality development in the pharmaceutical industry and guaranteeing access to quality and affordable medicines. In general, there is support for an effective market and a combination of government, a guarantee of security, a governance that offers a range of reform initiatives from a full-cycle, full-channel, cross-cutting perspective。
Twenty-one points: for a long time, we have continuously optimized the mechanisms for drug prices, but there are still many difficulties in practice. The opinions set up a system of price formation for drugs that is classified, paid in multiple ways, and managed in a chain-wide and coordinated manner, giving limited pricing power to enterprises, introducing corporate self-assessment and autonomous pricing, and providing significant incentives for innovative drug development and market supply。
The nhs publicly solicits comments from the medical pathological cloud index program, health pathological cloud data set
In order to safeguard the rights and interests of the insured persons, the national health and safety institute (nss) has carried out research on the health care pathological cloud index, promoting the pathological examination data “available to the patient himself, accessible to the medical institution and approved by the health services”. It focuses on the whole process management of pathological examinations, in accordance with the principles of “process continuity, sole element, standard harmonization and traceability”, resulting in the health pathological cloud indexing programme (approval draft) and the medical pathological cloud data set (approval draft), which is now open to public comment. The public may comment on a variety of aspects, such as index structure, field definition, and provide feedback in written or e-mail form by 18:00 on 22 april 2026。
Medicine approval
Hen suri medicines: the subsidiary hrs-7156 were approved in clinical trials
On 15 april, the han shwe medicines (600276. Sh) announced that the company's subsidiary, shandong shenty medicines ltd., had recently received approval from the national bureau of medicine and medicine to issue a letter of approval for the medical clinical trial of hrs-7156 tablets, agreeing to conduct clinical trials. The drug is a new type of drug developed by the company on its own, applying for adaptive disorders as heart failure. Pre-clinical data show that hrs-7156 can significantly improve heart function and pathologies, and no such drugs are currently licensed either in the country or abroad. To date, the cumulative research and development investment of the project has been approximately $37. 6 million。
Xinhua pharmaceuticals: certificate of registration for bulmetini injecting liquid drugs
On 15 april, xinhua pharmaceuticals (000756. Sz) announced that the company had recently received an approval from the national drug authority to issue a certificate of registration for the medication of bumetani injections. The drug, which is a 3-prescription drug for chemical drugs, is used for treatment of edema, hypertension and acute kidney failure, and belongs to the category b of the 2025 version of the national health insurance directory。
Industry issues
New mileage: proposed indirect acquisition of 65 per cent of the shares in the company secondary hospital
On 15 april, the new mile (002219. Sz) announced that the company had signed an acquisition framework agreement with the controlling shareholder, new mile health industries group limited of beijing (known as the “new mile group”) to indirectly acquire 65 per cent of the shares of taiwon medium secondary hospital ltd., i. E., a limited liability company (hereinafter referred to as “spv”) established by the new mile group of company controlling shareholders and/or the subject under its control, and that the spv would first acquire 65 per cent of the shares held by beijing hong kong merciful medical investment management ltd., the company and/or its subsidiaries would acquire 100 per cent of the shares in spv and 65 per cent of the shares indirectly。
Financial information
Ed biological: net profits increased by 41. 7 per cent in 2025
Ed biology (300685. Sz) published its 2025 annual report, which showed that the company's operating income amounted to 1,198 million yuan, an increase of 8. 01 per cent over the same period; the net profits attributed to the shareholders of the listed companies were 361 million yuan, an increase of 41. 74 per cent over the same period. In addition, the company announced the discovery of a gold dividend of $4. 5 per ten shares for all shareholders. This performance and bonus scheme demonstrates the firm's steady growth in the health sector and the importance it attaches to shareholder returns。
Net profits to mothers increased by 15. 26 per cent in 2025
New and sing (002001. Sz) issued an annual report for 2025, which resulted in an operating income of 22,251 million yuan, an increase of 2. 97 per cent over the same period; net profits attributable to shareholders in listed companies amounted to 6,764 million yuan, an increase of 15. 26 per cent over the same period. The net profit after deduction of non-recurrent gains and losses was $6,738 million, an increase of 15. 59 per cent over the same period. The basic per share income was $2. 21. The company continues to grow in the market for vitamins, pigments and spices, prices for omelet acid have risen, and new materials and raw materials have performed well. Companies have also been active in promoting new product markets, expanding new applications and emerging markets, and increasing production efficiency. In addition, the company intends to find a gold dividend of $8. 00 (including taxes) for every 10 shares of all shareholders。
Capital markets
Building blocks: proposed distribution of 118 million new shares and net mobilization of approximately 1,053 million hong kongs dollar
In the early morning of 15 april, the essential medicine industry was announced in hong kong, and on 14 april 2026 (after the time of the transaction) the company entered into a distribution agreement with the distributor, under which the company had agreed to sell a total of 118 million shares of its share to not less than six of its partners at the price of hk$8. 97 per share. On the assumption that all shareholdings are allocated, the net proceeds from the allocation are estimated at hk$ 1,053. 17 million. The net proceeds from the sale are expected to be used for 90 per cent of the further development related to assets in the group “line 2. 0”, in particular for cs 2009, cs5001 and other assets in the pre-clinical or ind preparatory phase, and for other general corporate purposes, as appropriate。
Smart and healthy completion of seed wheel financing
In recent days, the prophylaxis health (rehealth ai) announced the completion of a 4 million yuan rmb seed ship financing, with a post-investment valuation of 25 million rmb, undisclosed. Investors provide financial support while providing deep synergies at the operational level. This round of funding will be used for small-scale clinical retrospect testing, second-class medical equipment software disclosure, algorithms and models filing, and prediction-intervention- psm attribution - project landing for settlement verification of complete closed loops。
Early warning
Harvard update: 80 per cent of the initial diagnosis with the ai large language model is wrong
On 15 april, a research team from harvard medical school in the united states assessed the diagnostic capabilities of more than 20 of the most advanced major ai language models (llm), including chatgpt, deepseek, gemini and claude. The results show an error rate of up to 80 per cent in the “identifying diagnosis” (identifying possible diseases) based on the patient's initial symptoms and signs. The study further shows that, with more results from patients, large models can reduce the failure rate of “final diagnosis” to around 40 per cent. According to researchers, this means that ai chat robots need adequate patient information in order to be able to diagnose the disease more precisely, and the results provided by ai are unreliable when patients are unable to provide complete health information. Researchers also stress that “advisory intelligence has not reached the level of diagnostic decision-making for patients without the intervention of medical professionals”
